Skip to content

Cash ratio at other companies

Pfizer logo
PfizerPFE
0.1×0.0×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
+1.8×
Summit Therapeutics logo
Summit TherapeuticsSMMT
0.1×-0.1×
Exelixis logo
ExelixisEXEL
0.6×+0.1×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
1.5×-0.6×
Incyte logo
IncyteINCY
2.3×+1.2×

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Calculated from Nuvalent, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s cash ratio?
Nuvalent, Inc. (NUVL) reported cash ratio of 2× in Q1 2026.
How has Nuvalent, Inc.'s cash ratio changed year-over-year?
Nuvalent, Inc.'s cash ratio increased by 22.4% year-over-year, from 1.6× to 2×.
What is the long-term trend for Nuvalent, Inc.'s cash ratio?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s cash ratio has grown at a 4.0% compound annual growth rate (CAGR), from 2.4× to 2.9×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.